News & Updates

Novel tri-agonist confers significant gains for MASLD patients
Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023 byAudrey Abella

In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.

Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023
Asthma education, control test help lower exacerbations risks
Asthma education, control test help lower exacerbations risks
23 Nov 2023 byStephen Padilla

The presence of asthma education and Asthma Control Test (ACT) may prevent exacerbations or at least delay the onset of severe exacerbations, suggests a Singapore study.

Asthma education, control test help lower exacerbations risks
23 Nov 2023